PhysIQ Inc. Receives FDA Clearance of Continuous Ambulatory Respiration Rate Algorithm Enabling Artificial Intelligence-based Analytics for Biopharma Companies and Payers

CHICAGO – PhysIQ, a leader in applying artificial intelligence to wearable sensor data, today announced that it has received 510(k) clearance from the U.S. Food and Drug Administration (FDA) for their algorithm to continuously determine respiration rate in ambulatory patients. This clearance adds to their expanding portfolio of FDA-cleared cloud-based analytics, which also include QRS detection, heart rate, heart rate variability, atrial fibrillation detection, and their personalized physiology change detection analytic.